Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

New French biotechnology company formed to develop MAb for ovarian cancer

Oct. 2, 2013

Results of phase III trial demonstrate improvements in PFS and PSA responses with ipilimumab

Oct. 1, 2013

Etubics receives SBIR grant for breast cancer immunotherapeutic

Oct. 1, 2013

Phase I results show promising oncolytic activity for the anti-HB-EGF antibody U3-1565

Sep. 30, 2013

Eli Lilly reports topline results from two global phase III ramucirumab studies

Sep. 30, 2013

Mologen submits MGN-1703 IND application with FDA

Sep. 27, 2013

Bio-Matrix Scientific provides update on dCellVax for breast cancer

Sep. 27, 2013

Merck KGaA to renew testing of lung cancer vaccine

Sep. 27, 2013

Trastuzumab emtansine receives committee recommendation in E.U.

Sep. 23, 2013

OncoMed Pharmaceuticals begins phase Ib/II trial of demcizumab in ovarian cancer

Sep. 23, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
Fortvita and Innovent patent new anti-TROP2/B7-H4 ADCs
BioWorld Science
Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or...